Cannabis and Cannabinoids in the Treatment of Rheumatic Diseases
Authors:
Open Access
- 30 January 2020
- journal article
- review article
- Published by Rambam Health Corporation in Rambam Maimonides Medical Journal
- Vol. 11 (1) , e0007
Abstract
Chronic pain is a common complaint among patients, and rheumatic diseases are a common cause for chronic pain. Current pharmacological interventions for chronic pain are not always useful or safe enough for long-term use. Cannabis and cannabinoids are currently being studied due to their potential as analgesics. In this review we will discuss current literature regarding cannabinoids and cannabis as treatment for rheumatic diseases. Fibromyalgia is a prevalent rheumatic disease that causes diffuse pain, fatigue, and sleep disturbances. Treatment of this syndrome is symptomatic, and it has been suggested that cannabis and cannabinoids could potentially alleviate some of the symptoms associated with fibromyalgia. In this review we cite some of the evidence that supports this claim. However, data on long-term efficacy and safety of cannabinoid and cannabis use are still lacking. Cannabinoids and cannabis are commonly investigated as analgesic agents, but in recent years more evidence has accumulated on their potential immune-modulatory effect, supported by results in animal models of certain rheumatic diseases. While results that demonstrate the same effect in humans are still lacking, cannabinoids and cannabis remain potential drugs to alleviate the pain associated with rheumatic diseases, as they were shown to be safe and to cause limited adverse effects.Keywords
This publication has 45 references indexed in Scilit:
- Taming THC: potential cannabis synergy and phytocannabinoid‐terpenoid entourage effectsBritish Journal of Pharmacology, 2011
- Fibromyalgia and neuropathic pain - differences and similarities. A comparison of 3057 patients with diabetic painful neuropathy and fibromyalgiaBMC Neurology, 2011
- Cannabis Use in Patients with Fibromyalgia: Effect on Symptoms Relief and Health-Related Quality of LifePLOS ONE, 2011
- Targeting the Cannabinoid Pathway Limits the Development of Fibrosis and Autoimmunity in a Mouse Model of Systemic SclerosisThe American Journal of Pathology, 2010
- EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revisionEuropean Journal of Neurology, 2010
- The Effects of Nabilone on Sleep in Fibromyalgia: Results of a Randomized Controlled TrialAnesthesia & Analgesia, 2010
- Neurobiology of depression, fibromyalgia and neuropathic painFrontiers in Bioscience-Landmark, 2009
- Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritisArthritis Research & Therapy, 2008
- The burden of musculoskeletal disease—a global perspectiveClinical Rheumatology, 2006
- Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritisRheumatology, 2005